| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | HDGC; CDHF5; ARVC10; ARVD10; CMD1BB |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human DSG2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DSG2抗体的3篇代表性文献摘要：
1. **文献名称**：*"Desmoglein 2 is a receptor for adenovirus serotypes 3. 7. 11 and 14"*
**作者**：Wang H et al.
**摘要**：该研究首次发现DSG2是多种腺病毒亚型(如Ad3、Ad7)的细胞表面受体，揭示了DSG2抗体可能通过阻断病毒入侵发挥治疗作用，为抗病毒药物开发提供了新靶点。
2. **文献名称**：*"Anti-desmoglein 2 autoantibodies in the pathogenesis of arrhythmogenic right ventricular cardiomyopathy"*
**作者**：López-Ayala JM et al.
**摘要**：研究发现，针对DSG2的自身抗体与致心律失常性右室心肌病(ARVC)相关，可能导致心肌细胞间黏附功能受损，引发心肌纤维化和心律失常，提示DSG2抗体可能参与疾病进展。
3. **文献名称**：*"Targeting DSG2 in cancer: Monoclonal antibody therapy inhibits tumor growth in preclinical models"*
**作者**：Chen Y et al.
**摘要**：该研究开发了一种靶向DSG2的单克隆抗体，在结直肠癌和乳腺癌动物模型中显示出显著抑制肿瘤生长的效果，机制可能与阻断DSG2介导的细胞迁移和信号通路有关。
(注：以上文献信息为模拟示例，实际引用需根据具体数据库检索确认。)
Desmoglein-2 (DSG2) is a transmembrane glycoprotein belonging to the desmoglein subfamily of cadherins, primarily involved in cell-cell adhesion through desmosomes—specialized intercellular junctions critical for tissue integrity. Expressed ubiquitously in epithelial and myocardial tissues, DSG2 plays a vital role in maintaining structural stability and mechanical resilience in tissues subjected to stress, such as the skin, heart, and gastrointestinal tract. Beyond its structural function, DSG2 participates in signaling pathways regulating cell proliferation, differentiation, and apoptosis, linking it to pathological processes like cancer progression and cardiovascular diseases.
DSG2 antibodies, either autoantibodies or research tools, have significant clinical and experimental relevance. In autoimmune disorders like paraneoplastic pemphigus or arrhythmogenic cardiomyopathy, autoantibodies against DSG2 disrupt desmosomal adhesion, leading to tissue blistering or myocardial dysfunction. In cancer research, DSG2 overexpression is observed in certain carcinomas (e.g., gastric, colorectal), and DSG2-targeting antibodies are explored for diagnostic or therapeutic purposes. For example, monoclonal antibodies against DSG2 are studied for their potential to inhibit tumor growth or enhance drug delivery by binding overexpressed DSG2 on cancer cells.
However, DSG2 antibodies also pose challenges. Their cross-reactivity with other desmogleins or unintended tissues may complicate therapeutic applications. Additionally, cardiac toxicity risks limit the use of DSG2-targeting agents due to the protein’s critical role in myocardial integrity. Ongoing research aims to refine antibody specificity and evaluate their dual role as biomarkers and therapeutic targets in diseases linked to desmosomal dysfunction.
×
